34969-79-4

Upstream product

• 2491-38-5 2-bromo-1-(4'-hydroxyphenyl)-1-ethanone 
• 99-93-4 4-Hydroxyacetophenone 
• 2887-72-1 1-(3,5-dibromo-4-hydroxyphenyl)ethan-1-one 

Downstream Products

• 1191246-64-6 2,6-dibromo-4-(3-((naphthalen-1-yloxy)methyl)-1,2,4-triazin-6-yl)phenol 
• 1192706-89-0 (4-benzylpiperidin-1-yl)(4-(3,5-dibromo-4-hydroxyphenyl)thiazol-2-yl)methanone 
• 1192707-08-6 4-(3,5-dibromo-4-hydroxy-phenyl)-thiazole-2-carboxylic acid 
• 1198153-69-3 1-(3,5-dibromo-4-hydroxy-phenyl)-2-(2,3-dihydro-pyrido[4,3-b][1,4]oxazin-4-yl)-ethanone 
• 1198153-71-7 4-[2-(3,5-dibromo-4-hydroxy-phenyl)-2-oxo-ethyl]-4H-pyrido[4,3-b][1,4]oxazin-3-one 
• 1192707-07-5 4-(3,5-dibromo-4-hydroxy-phenyl)-thiazole-2-carboxylic acid ethyl ester 
• 1422285-73-1 C₈H₈Br₂NO₂⁽¹⁺⁾*Br^(1-) 
• 1422285-81-1 C₂₁H₁₇Br₄ClN₂O₂ 
• 1422285-80-0 C₂₂H₂₁Br₃ClN₃O₂ 
• 1422285-79-7 C₂₃H₂₃Br₃ClN₃O₂ 
• 1422285-78-6 C₁₈H₁₂Br₃ClN₂O₂ 
• 1422285-77-5 C₁₈H₁₃Br₃N₂O₃ 
• 1422285-76-4 C₁₈H₁₄Br₃NO₅ 
• 1422285-71-9 C₁₄H₁₇Br₂N₄O₂⁽¹⁺⁾*Br^(1-) 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists

Most of reported steroidal FXR antagonists are restricted due to low potency. We described the design and synthesis of novel nonsteroidal scaffold SIPI-7623 derivatives as FXR antagonists. The most potent compound A-11 (IC50 = 7.8 ± 1.1 μM) showed better activity compared to SIPI-7623 (IC50 = 40.8 ± 1.7 μM) and guggulsterone (IC50 = 45.9 ± 1.1 μM). Docking of A-11 in FXR’s ligand-binding domain was also studied.

COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT

Provided are a compound as represented in formula (I), a pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and uses thereof. The compound as represented in formula (I) and the pharmaceutically acceptable salts thereof are used in the preparation of medicines for the treatment or prevention of hyperuricemia or gout by means of uric acid excretion.

The first total synthesis and biological evaluation of marine natural products ma'edamines A and B

We have developed the first total syntheses of marine natural products ma'edamines A (18) and B (20). Structurally, they contain a pyrazine-2-(1H)-one core and were screened for antiproliferative activity on several cancer cell lines. Out of the six cell lines tested, ma'edamines A and B showed significant cytotoxicity against human colon cancer line COLO 205 (IC50 7.9 and 10.3 μM, respectively), breast cancer cell line MCF-7 (IC50: 6.9 and 10.5 μM, respectively) and human lung adenocarcinoma cell line A549 (IC50: 12.2 and 15.4 μM, respectively). The apoptotic effect of ma'edamines was confirmed by comet assay. Hence ma'edamines are likely to be useful as leads for development of a new class of anti-cancer agents.

HETEROCYCLIC DERIVATIVES

The present invention relates to heterocyclic derivatives, and more particularly, to novel heterocyclic derivatives useful for the preparation of medicaments for treating diseases related to uric acid.

Compounds, Compositions and Methods Comprising Triazine Derivatives

The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or encompassed by formulas I-II) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives

The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.